OS Therapies Incorporated

AMEX:OSTX

Biotechnology

Healthcare
$1.15 +5.81%

+$0.10 today

Market cap
$53.83M
Beta
-0.95
P/E (TTM)
-2.0
EPS (TTM)
-$0.91
52W Low $1.15High $2.57

Volume 0.50M

Average 0.71M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$14.24B

FY 2025 · Annual

Investing Cash Flow

-$466.42M

FY 2025 · Annual

Financing Cash Flow

$9.44B

FY 2025 · Annual

+73793.9% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(7.42M)(6.25M)(7.79M)(8.88M)(28.75B)
Depreciation & Amortization8058054.22K2.78K363.09M
Deferred Income Tax00000
Stock-Based Compensation000268.3K4.27B
Change in Working Capital574.67K947.33K2.02M(129.64K)9.11M
Accounts Receivables00000
Inventory00000
Accounts Payables856.48K216.43K1.35M(1.05M)8.27M
Other Working Capital(281.81K)730.9K669.65K923.69K834.81K
Other Non-Cash Items2.44M1.51M2.76M1.46M9.88B
Operating Cash Flow(4.4M)(3.79M)(3.01M)(7.28M)(14.24B)
Capital Expenditures(11.93K)000(466.42K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities212.41K230.88K1.15K0(465.96M)
Investing Cash Flow200.47K230.88K1.15K0(466.42M)
Debt Repayment2.95M3.82M3.16M1.5M0
Common Stock Issued0005.23M8.39M
Common Stock Repurchased00000
Dividends Paid000(31.25M)0
Other Financing Activities100K(172.02K)(284.18K)31.25M9.43B
Financing Cash Flow3.05M3.65M2.87M12.78M9.44B
Effect of Forex Changes00000
Net Change in Cash(1.15M)90.69K(132.5K)5.49M(5.26B)
Free Cash Flow(4.41M)(3.79M)(3.01M)(7.28M)(14.24B)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$28.8B
+ D&A$363.1M
+ Stock-Based Comp$4.3B
+ Deferred Tax$0
+ Working Capital$9.1M
+ Other Non-Cash$9.9B
= Operating Cash Flow-$14.2B
- Capex-$466.4K
= Free Cash Flow-$14.2B

Analysis

FY2025 free cash flow is -$14.2B. FCF conversion is 49.5% of net income. Operating cash flow was -$14.2B, with capex of -$466.4K. The largest bridge item is Other Non-Cash at $9.9B.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026

Does OSTX generate free cash flow?

OS Therapies Incorporated (OSTX) generated -$14.24B of free cash flow in fiscal 2025.

How much operating cash flow does OSTX produce?

Operating cash flow was -$14.24B, before capital expenditures of $466,423.00.